New Fully Absorbable Patch Based Large Hole Vascular Closure Device Presented by Priv.-Doz. Dr. med. Michael Laule Charité University Hospital, Berlin, Germany
Potential conflicts of interest Speaker's name: Priv.-Doz. Dr. med. Michael Laule q I have the following potential conflicts of interest to report: Affiliation/Financial Relationship Company • • Grant/Research Support Vivasure Medical
Primary Drivers of Clinical Need Desired Approach: TAVR TEVAR Fully percutaneous EVAR Easy to use ECMO Safe and secure Fully bioabsorbable Challenge: Complications associated with currently available large hole closure devices
Fully absorbable patch based Simple operation (OTW) Indicated 18F - 24F arteriotomies No suture, collagen or metal components Absorbed fully within 180 days in animal model
Pre-clinical Histopathology: 30-180 days post implantation Implant Implant Implant Absorbed Encapsulated absorbing and extra-arterial Cross-section Cross-section Cross-section @ 32 days @ 91 days @ 180 days Porcine abdominal aorta – luminal surface 22F Arteriotomy Complete absorption Implantation site Implantation site undifferentiated from native arterial wall No granuloma/scaring Longitudinal histology @ No perivascular fibrosis 162 days
Frontier III - Multi-centred European Clinical Study Aim of the Study: Assess the safety and clinical performance of a new fully percutaneous patch based synthetic absorbable Large Hole Closure Device (18-24F). Method: 50+ patients undergoing large bore femoral percutaneous access for TAVI, EVAR and TEVAR, prospective, non-randomized in 6 European centres Assessment of puncture site with DUS/CT at discharge, 30 days, 90 days and 1 year Primary endpoint: Incidence and severity of major complication rates directly related to the VIVASURE CLOSURE DEVICE up to 3 months from implantation (as defined by VARC-2) is no worse than those associated with cut-down or suture based closure devices of 14.7%
Frontier III - Clinical Case Primary Procedure: TAVR with Edwards Sapien 3 Device 29mm Valve Closure Procedure: PerQseal Device 21F Closure
Frontier III - Results 62 subjects (70 closures) completed across 6 European centers Follow-up Subjects Procedures No. Discharge 62 TAVR 42 3 Month 59 EVAR 24 12 Month 42 TEVAR 4 Mix of devices and sheath sizes across procedures No device related major vascular complications (VARC-2) 97% technical success 3 minor device related complications (haematoma, asymptomatic stenosis and pseudoaneurysm No late minor or major device related vascular complications No clinically significant changes on ultrasound or CT-Angiogram
NEXT STEPS Build clinical experience Indication expansion – (Frontier IV study) Post market – registries EU commercialisation Prepare for US IDE study
Summary Easy to use device with low learning curve Patch-based, fully bioabsorbable implant Requires no pre-procedure steps Has clinically demonstrated its safety and effectiveness with excellent outcomes from discharge through 1, 3 and 12 month follow-up (120 patients in Frontier I, II and III) Device provides a real option for fully percutaneous closure with the potential to reduce hospital costs and procedure times
New Fully Absorbable Patch Based Large Hole Vascular Closure Device Jeffrey
Interactive Visualization and On-Demand Processing of Large Volume Data: A
ence ce eren Confer A Fully A Fu lly GPU GPU-Based Based Ou Out-Of
4/17/2018 Global Vascular Guideline on the Management of Chronic Limb
Fac acial ial Ex Expression ression Det etecti ection on using ng Pat
Academic vs. Clinically -based Vascular Surgery Fellowships John E. Rectenwald
Soft-Hair Enhanced Entanglement Beyond Page Curves in Black-Hole Evaporation
4/7/2017 Disclosure Optimizing The Performance Of None Your Vascular Lab
Vascular Annual Meeting General Surgery Resident Breakfast Program May 30,
An Analysis of Patch Plausibility and Correctness of Generate-And-
Perspectives on POCUS - Handout from STFM Conference Presentation 4/2019 A
FSI Simulation of Pulsatile Blood Flow in Aortic Arch (coupling Abaqus and
Connie Lorette, PhD, CRNA Intraoperative monitoring ASE/SCA assess 20 view
30-05-11 Clinical outcome after pre-incision Aim Study assessment of
Sub-aortic stenosis in England 1997 2015: Reoperation rates and risk factors
Hello, my name is Ka.e Girgulis and I am a medical student at the
Three-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in
THE HEART THE HEART MEDIASTINUM PERICARDIUM HEART THE HEART THE
Improving the Efficiency of Manual Ground Truth Labeling Using Automated
Late Presentation of Turner Syndrome and Its Complications Huzairi Sani 1 ,
Tirone David-V S mod V-SARR for Bicuspid Aortic Valve (BAV) Aortopathy and AR
ECMO. In the Emergency Department John C. Greenwood, MD Department of